Cargando…

Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs

Fatty acid binding proteins (FABPs), in particular FABP5 and FABP7, have recently been identified by us as intracellular transporters for the endocannabinoid anandamide (AEA). Furthermore, animal studies by others have shown that elevated levels of endocannabinoids resulted in beneficial pharmacolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, William T., Ralph, Brian P., Kaczocha, Martin, Sun, Jing, Balius, Trent E., Rizzo, Robert C., Haj-Dahmane, Samir, Ojima, Iwao, Deutsch, Dale G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517626/
https://www.ncbi.nlm.nih.gov/pubmed/23236415
http://dx.doi.org/10.1371/journal.pone.0050968
_version_ 1782252462769438720
author Berger, William T.
Ralph, Brian P.
Kaczocha, Martin
Sun, Jing
Balius, Trent E.
Rizzo, Robert C.
Haj-Dahmane, Samir
Ojima, Iwao
Deutsch, Dale G.
author_facet Berger, William T.
Ralph, Brian P.
Kaczocha, Martin
Sun, Jing
Balius, Trent E.
Rizzo, Robert C.
Haj-Dahmane, Samir
Ojima, Iwao
Deutsch, Dale G.
author_sort Berger, William T.
collection PubMed
description Fatty acid binding proteins (FABPs), in particular FABP5 and FABP7, have recently been identified by us as intracellular transporters for the endocannabinoid anandamide (AEA). Furthermore, animal studies by others have shown that elevated levels of endocannabinoids resulted in beneficial pharmacological effects on stress, pain and inflammation and also ameliorate the effects of drug withdrawal. Based on these observations, we hypothesized that FABP5 and FABP7 would provide excellent pharmacological targets. Thus, we performed a virtual screening of over one million compounds using DOCK and employed a novel footprint similarity scoring function to identify lead compounds with binding profiles similar to oleic acid, a natural FABP substrate. Forty-eight compounds were purchased based on their footprint similarity scores (FPS) and assayed for biological activity against purified human FABP5 employing a fluorescent displacement-binding assay. Four compounds were found to exhibit approximately 50% inhibition or greater at 10 µM, as good as or better inhibitors of FABP5 than BMS309403, a commercially available inhibitor. The most potent inhibitor, γ-truxillic acid 1-naphthyl ester (ChemDiv 8009-2334), was determined to have K(i) value of 1.19±0.01 µM. Accordingly a novel α-truxillic acid 1-naphthyl mono-ester (SB-FI-26) was synthesized and assayed for its inhibitory activity against FABP5, wherein SB-FI-26 exhibited strong binding (K(i) 0.93±0.08 µM). Additionally, we found SB-FI-26 to act as a potent anti-nociceptive agent with mild anti-inflammatory activity in mice, which strongly supports our hypothesis that the inhibition of FABPs and subsequent elevation of anandamide is a promising new approach to drug discovery. Truxillic acids and their derivatives were also shown by others to have anti-inflammatory and anti-nociceptive effects in mice and to be the active component of Chinese a herbal medicine (Incarvillea sinensis) used to treat rheumatism and pain in humans. Our results provide a likely mechanism by which these compounds exert their effects.
format Online
Article
Text
id pubmed-3517626
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35176262012-12-12 Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs Berger, William T. Ralph, Brian P. Kaczocha, Martin Sun, Jing Balius, Trent E. Rizzo, Robert C. Haj-Dahmane, Samir Ojima, Iwao Deutsch, Dale G. PLoS One Research Article Fatty acid binding proteins (FABPs), in particular FABP5 and FABP7, have recently been identified by us as intracellular transporters for the endocannabinoid anandamide (AEA). Furthermore, animal studies by others have shown that elevated levels of endocannabinoids resulted in beneficial pharmacological effects on stress, pain and inflammation and also ameliorate the effects of drug withdrawal. Based on these observations, we hypothesized that FABP5 and FABP7 would provide excellent pharmacological targets. Thus, we performed a virtual screening of over one million compounds using DOCK and employed a novel footprint similarity scoring function to identify lead compounds with binding profiles similar to oleic acid, a natural FABP substrate. Forty-eight compounds were purchased based on their footprint similarity scores (FPS) and assayed for biological activity against purified human FABP5 employing a fluorescent displacement-binding assay. Four compounds were found to exhibit approximately 50% inhibition or greater at 10 µM, as good as or better inhibitors of FABP5 than BMS309403, a commercially available inhibitor. The most potent inhibitor, γ-truxillic acid 1-naphthyl ester (ChemDiv 8009-2334), was determined to have K(i) value of 1.19±0.01 µM. Accordingly a novel α-truxillic acid 1-naphthyl mono-ester (SB-FI-26) was synthesized and assayed for its inhibitory activity against FABP5, wherein SB-FI-26 exhibited strong binding (K(i) 0.93±0.08 µM). Additionally, we found SB-FI-26 to act as a potent anti-nociceptive agent with mild anti-inflammatory activity in mice, which strongly supports our hypothesis that the inhibition of FABPs and subsequent elevation of anandamide is a promising new approach to drug discovery. Truxillic acids and their derivatives were also shown by others to have anti-inflammatory and anti-nociceptive effects in mice and to be the active component of Chinese a herbal medicine (Incarvillea sinensis) used to treat rheumatism and pain in humans. Our results provide a likely mechanism by which these compounds exert their effects. Public Library of Science 2012-12-07 /pmc/articles/PMC3517626/ /pubmed/23236415 http://dx.doi.org/10.1371/journal.pone.0050968 Text en © 2012 Berger et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Berger, William T.
Ralph, Brian P.
Kaczocha, Martin
Sun, Jing
Balius, Trent E.
Rizzo, Robert C.
Haj-Dahmane, Samir
Ojima, Iwao
Deutsch, Dale G.
Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs
title Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs
title_full Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs
title_fullStr Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs
title_full_unstemmed Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs
title_short Targeting Fatty Acid Binding Protein (FABP) Anandamide Transporters – A Novel Strategy for Development of Anti-Inflammatory and Anti-Nociceptive Drugs
title_sort targeting fatty acid binding protein (fabp) anandamide transporters – a novel strategy for development of anti-inflammatory and anti-nociceptive drugs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517626/
https://www.ncbi.nlm.nih.gov/pubmed/23236415
http://dx.doi.org/10.1371/journal.pone.0050968
work_keys_str_mv AT bergerwilliamt targetingfattyacidbindingproteinfabpanandamidetransportersanovelstrategyfordevelopmentofantiinflammatoryandantinociceptivedrugs
AT ralphbrianp targetingfattyacidbindingproteinfabpanandamidetransportersanovelstrategyfordevelopmentofantiinflammatoryandantinociceptivedrugs
AT kaczochamartin targetingfattyacidbindingproteinfabpanandamidetransportersanovelstrategyfordevelopmentofantiinflammatoryandantinociceptivedrugs
AT sunjing targetingfattyacidbindingproteinfabpanandamidetransportersanovelstrategyfordevelopmentofantiinflammatoryandantinociceptivedrugs
AT baliustrente targetingfattyacidbindingproteinfabpanandamidetransportersanovelstrategyfordevelopmentofantiinflammatoryandantinociceptivedrugs
AT rizzorobertc targetingfattyacidbindingproteinfabpanandamidetransportersanovelstrategyfordevelopmentofantiinflammatoryandantinociceptivedrugs
AT hajdahmanesamir targetingfattyacidbindingproteinfabpanandamidetransportersanovelstrategyfordevelopmentofantiinflammatoryandantinociceptivedrugs
AT ojimaiwao targetingfattyacidbindingproteinfabpanandamidetransportersanovelstrategyfordevelopmentofantiinflammatoryandantinociceptivedrugs
AT deutschdaleg targetingfattyacidbindingproteinfabpanandamidetransportersanovelstrategyfordevelopmentofantiinflammatoryandantinociceptivedrugs